Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Cancers|December 19, 2019
Low Systemic Levels of Chemokine C-C Motif Ligand 3 (CCL3) are Associated with a High Risk of Venous Thromboembolism in Patients with GliomaPegah Mir Seyed Nazari, Christine Marosi, Florian Moik, et al.
Blood Advances|January 26, 2021
Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancerYohei Hisada, Kenison B Garratt, Anaum Maqsood, et al.
Frontiers in Cardiovascular Medicine|September 2, 2022
Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancerFlorian Posch, Tobias Niedrist, Theresa Glantschnig, et al.
Scientific Reports|August 29, 2025
Podoplanin expression is associated with local inflammation and survival in gliomaPegah Mir Seyed Nazari, Maximilian J Mair, Julia Riedl, et al.
ESMO Open|May 20, 2020
Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with gliomaPegah Mir Seyed Nazari, Anna S Berghoff, Matthias Preusser, et al.
Journal of Thrombosis and Haemostasis : JTH|February 16, 2025
Arterial thromboembolic events in testicular cancer patients: short- and long-term incidence, risk factors, and impact on mortalityFlorian Moik, Angelika Terbuch, Ariane Sprakel, et al.
ESMO Open|September 4, 2020
SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemicThorsten Fuereder, Anna Sophie Berghoff, Gerwin Heller, et al.
Future Oncology (London, England)|March 20, 2026
AGMT mCRC Registry Third-Line and Beyond: a multicentric real-world platform with integrated imaging and biosample database for later-line metastatic colorectal cancerFlorian Huemer, Gudrun Piringer, Wolfgang Eisterer, et al.
Scientific Reports|April 5, 2019
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysisFlorian Moik, Jakob M Riedl, Thomas Winder, et al.
European Journal of Cancer (Oxford, England : 1990)|May 5, 2021
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysisJakob M Riedl, Florian Posch, Lena Horvath, et al.
Pageof 6